Royal Bank of Canada’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $98.3M | Buy |
583,476
+251,176
| +76% | +$37.3M | 0.01% | 707 |
|
|
2026
Q1 | $43.8M | Buy |
332,300
+21,288
| +7% | +$2.82M | 0.01% | 981 |
|
|
2025
Q4 | $44.1M | Buy |
311,012
+66,336
| +27% | +$9.61M | 0.01% | 1008 |
|
|
2025
Q3 | $34.3M | Buy |
244,676
+123,524
| +102% | +$16.7M | 0.01% | 1231 |
|
|
2025
Q2 | $15.2M | Buy |
121,152
+38,342
| +46% | +$4.4M | ﹤0.01% | 1723 |
|
|
2025
Q1 | $9.16M | Buy |
82,810
+22,224
| +37% | +$2.82M | ﹤0.01% | 1807 |
|
|
2024
Q4 | $8.27M | Sell |
60,586
-192,324
| -76% | -$23.8M | ﹤0.01% | 1933 |
|
|
2024
Q3 | $29.1M | Buy |
252,910
+87,481
| +53% | +$12M | 0.01% | 1111 |
|
|
2024
Q2 | $22.8M | Buy |
165,429
+26,455
| +19% | +$3.63M | 0.01% | 1177 |
|
|
2024
Q1 | $19.2M | Buy |
138,974
+16,427
| +13% | +$2.24M | ﹤0.01% | 1281 |
|
|
2023
Q4 | $16.1M | Buy |
122,547
+74,419
| +155% | +$8.57M | ﹤0.01% | 1411 |
|
|
2023
Q3 | $5.41M | Buy |
48,128
+4,233
| +10% | +$446K | ﹤0.01% | 2029 |
|
|
2023
Q2 | $4.14M | Sell |
43,895
-73,828
| -63% | -$7.21M | ﹤0.01% | 2240 |
|
|
2023
Q1 | $11.9M | Sell |
117,723
-3,629
| -3% | -$378K | ﹤0.01% | 1447 |
|
|
2022
Q4 | $14.5M | Buy |
121,352
+7,454
| +7% | +$873K | ﹤0.01% | 1362 |
|
|
2022
Q3 | $12.1M | Buy |
113,898
+5,973
| +6% | +$606K | ﹤0.01% | 1399 |
|
|
2022
Q2 | $10.5M | Buy |
107,925
+36,590
| +51% | +$3.38M | ﹤0.01% | 1539 |
|
|
2022
Q1 | $6.69M | Buy |
71,335
+9,810
| +16% | +$831K | ﹤0.01% | 2021 |
|
|
2021
Q4 | $5.24M | Buy |
61,525
+1,777
| +3% | +$163K | ﹤0.01% | 2351 |
|
|
2021
Q3 | $5.73M | Sell |
59,748
-7,731
| -11% | -$730K | ﹤0.01% | 2202 |
|
|
2021
Q2 | $6.57M | Buy |
67,479
+5,656
| +9% | +$542K | ﹤0.01% | 2123 |
|
|
2021
Q1 | $6.01M | Buy |
61,823
+4,242
| +7% | +$445K | ﹤0.01% | 2110 |
|
|
2020
Q4 | $5.52M | Buy |
57,581
+15,791
| +38% | +$1.53M | ﹤0.01% | 2136 |
|
|
2020
Q3 | $4.02M | Buy |
41,790
+12,122
| +41% | +$1.4M | ﹤0.01% | 2150 |
|
|
2020
Q2 | $3.62M | Buy |
29,668
+2,016
| +7% | +$223K | ﹤0.01% | 2171 |
|
|
2020
Q1 | $2.39M | Sell |
27,652
-1,756
| -6% | -$172K | ﹤0.01% | 2335 |
|
|
2019
Q4 | $3.16M | Buy |
29,408
+4,148
| +16% | +$434K | ﹤0.01% | 2484 |
|
|
2019
Q3 | $2.28M | Buy |
25,260
+2,119
| +9% | +$198K | ﹤0.01% | 2647 |
|
|
2019
Q2 | $1.95M | Sell |
23,141
-913
| -4% | -$75K | ﹤0.01% | 2795 |
|
|
2019
Q1 | $2.12M | Buy |
24,054
+514
| +2% | +$43K | ﹤0.01% | 2637 |
|
|
2018
Q4 | $1.68M | Buy |
23,540
+10,462
| +80% | +$1M | ﹤0.01% | 2769 |
|
|
2018
Q3 | $1.61M | Buy |
13,078
+1,242
| +10% | +$141K | ﹤0.01% | 3005 |
|
|
2018
Q2 | $1.16M | Buy |
11,836
+486
| +4% | +$43.5K | ﹤0.01% | 3118 |
|
|
2018
Q1 | $941K | Buy |
11,350
+3,428
| +43% | +$289K | ﹤0.01% | 3207 |
|
|
2017
Q4 | $615K | Sell |
7,922
-151,808
| -95% | -$10.4M | ﹤0.01% | 3646 |
|
|
2017
Q3 | $9.79M | Sell |
159,730
-1,801
| -1% | -$95K | ﹤0.01% | 1556 |
|
|
2017
Q2 | $7.43M | Sell |
161,531
-52,947
| -25% | -$2.57M | ﹤0.01% | 1704 |
|
|
2017
Q1 | $9.29M | Buy |
214,478
+205,610
| +2,319% | +$8.81M | 0.01% | 1531 |
|
|
2016
Q4 | $344K | Sell |
8,868
-27,357
| -76% | -$1.24M | ﹤0.01% | 4084 |
|
|
2016
Q3 | $1.83M | Sell |
36,225
-440,927
| -92% | -$22M | ﹤0.01% | 2615 |
|
|
2016
Q2 | $21.7M | Buy |
477,152
+14,449
| +3% | +$665K | 0.01% | 908 |
|
|
2016
Q1 | $18.3M | Buy |
462,703
+54,345
| +13% | +$2.16M | 0.01% | 981 |
|
|
2015
Q4 | $23.1M | Buy |
408,358
+397,967
| +3,830% | +$20.2M | 0.02% | 861 |
|
|
2015
Q3 | $414K | Sell |
10,391
-15,609
| -60% | -$754K | ﹤0.01% | 3698 |
|
|
2015
Q2 | $1.24M | Buy |
26,000
+8,400
| +48% | +$356K | ﹤0.01% | 2704 |
|
|
2015
Q1 | $699K | Sell |
17,600
-46,195
| -72% | -$1.65M | ﹤0.01% | 3195 |
|
|
2014
Q4 | $1.43M | Buy |
63,795
+57,695
| +946% | +$1.09M | ﹤0.01% | 2616 |
|
|
2014
Q3 | $96K | Hold |
6,100
| – | – | ﹤0.01% | 4639 |
|
|
2014
Q2 | $91K | Hold |
6,100
| – | – | ﹤0.01% | 4586 |
|
|
2014
Q1 | $98K | Buy |
6,100
+5,000
| +455% | +$85.5K | ﹤0.01% | 4555 |
|
|
2013
Q4 | $10K | Sell |
1,100
-2,100
| -66% | -$20.5K | ﹤0.01% | 5454 |
|
|
2013
Q3 | $36K | Sell |
3,200
-1,500
| -32% | -$20.6K | ﹤0.01% | 4938 |
|
|
2013
Q2 | $63K | Buy |
+4,700
| New | +$57.7K | ﹤0.01% | 4554 |
|
Other funds holding NBIX
Royal Bank of Canada's NBIX Position: Q2 2026 in Review
Royal Bank of Canada increased its Neurocrine Biosciences (NBIX) stake by 76% in Q2 2026, buying an estimated $37.3M and bringing the position to 583,476 shares worth $98.3M. The position accounts for 0.01% of the portfolio, ranked #707.
Royal Bank of Canada first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Royal Bank of Canada held 583,476 shares of Neurocrine Biosciences worth $98.3M as of Q2 2026.
- Royal Bank of Canada bought 251,176 Neurocrine Biosciences shares in Q2 2026, an estimated $37.3M.
- Neurocrine Biosciences made up 0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #707 holding.
- Royal Bank of Canada first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.